Literature DB >> 18294340

Chemokine-like factor expression in the idiopathic inflammatory myopathies.

M H Chowdhury1, A Nagai, M Terashima, A Sheikh, Y Murakawa, S Kobayashi, S Yamaguchi.   

Abstract

OBJECTIVES: We evaluated the expression of chemokine-like factor (CKLF) in biopsied muscle fibers in inflammatory myopathies, non-inflammatory myopathies and neurologically diseased controls.
MATERIALS AND METHODS: We studied the expression of CKLF in 15 polymyositis (PM), five dermatomyositis (DM), 15 non-inflammatory myopathies and nine neurologically diseased patients by immunohistochemistry.
RESULTS: Chemokine-like factor was mostly expressed in small diameter muscle fibers surrounded by infiltrated lymphocytes of inflammatory myopathies patients. Parts of them were also positive for the staining of the developmental form of myosin heavy chain, a maker of regenerating muscle fibers. Thrombin immunoreactivity was observed in endomysium in PM and perimysium in DM. In vitro differentiation study showed a constitutive expression of CKLF in myoblasts that was abolished in myotubes during differentiation process and was induced again by thrombin. Thrombin regulates CKLF expression through protease-activated receptor-1 in myotubes. Treatment of a protein kinase C inhibitor partially blocked CKLF expression in myoblasts, while it remarkably inhibited that in myotubes.
CONCLUSION: Chemokine-like factor expression is differentially regulated in myoblasts and myotubes. Thrombin could be a strong regulator for its expression. As CKLF is immunohistochemically positive in regenerating muscle fibers, we postulate here that CKLF is a useful marker for regenerating muscle fibers in inflammatory myopathies.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18294340     DOI: 10.1111/j.1600-0404.2007.00990.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  7 in total

1.  CMTM3 is frequently reduced in clear cell renal cell carcinoma and exhibits tumor suppressor activities.

Authors:  J Xie; Y Yuan; Z Liu; Y Xiao; X Zhang; C Qin; Z Sheng; T Xu; X Wang
Journal:  Clin Transl Oncol       Date:  2013-08-02       Impact factor: 3.405

2.  Antagonistic effect of C19 on migration of vascular smooth muscle cells and intimal hyperplasia induced by chemokine-like factor 1.

Authors:  Tao Zhang; Zhengguo Qiao; Feng Chen; Xiaoming Zhang; Jiang Xiong; Xin Jia; Jian Chen; Chenyang Shen; Wei Guo
Journal:  Mol Biol Rep       Date:  2012-12-01       Impact factor: 2.316

3.  CMTM4 is frequently downregulated and functions as a tumour suppressor in clear cell renal cell carcinoma.

Authors:  Ting Li; Yingying Cheng; Pingzhang Wang; Wenyan Wang; Fengzhan Hu; Xiaoning Mo; Hongxia Lv; Tao Xu; Wenling Han
Journal:  J Exp Clin Cancer Res       Date:  2015-10-16

4.  Chemokine-like factor-like MARVEL transmembrane domain-containing 3 expression is associated with a favorable prognosis in esophageal squamous cell carcinoma.

Authors:  Tianci Han; Tianci Shu; Siyuan Dong; Peiwen Li; Weinan Li; Dali Liu; Ruiqun Qi; Shuguang Zhang; Lin Zhang
Journal:  Oncol Lett       Date:  2017-03-10       Impact factor: 2.967

5.  Regulation of Acetylcholine Quantal Release by Coupled Thrombin/BDNF Signaling in Mouse Motor Synapses.

Authors:  Alexander Gaydukov; Polina Bogacheva; Ekaterina Tarasova; Anastasia Molchanova; Anna Miteva; Ekaterina Pravdivceva; Olga Balezina
Journal:  Cells       Date:  2019-07-22       Impact factor: 6.600

6.  Identification of cell surface proteins as potential immunotherapy targets in 12 pediatric cancers.

Authors:  Rimas J Orentas; James J Yang; Xinyu Wen; Jun S Wei; Crystal L Mackall; Javed Khan
Journal:  Front Oncol       Date:  2012-12-17       Impact factor: 6.244

7.  Chemokine-like factor 1 (CLFK1) is over-expressed in patients with atopic dermatitis.

Authors:  Gao-Yun Yang; Xue Chen; Ya-Chun Sun; Chen-Li Ma; Ge Qian
Journal:  Int J Biol Sci       Date:  2013-08-13       Impact factor: 6.580

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.